Tags

Type your tag names separated by a space and hit enter

Prevalence and clinical impact of polyomaviruses KI and WU in lung transplant recipients.
Transplant Proc. 2010 May; 42(4):1275-8.TP

Abstract

The newly discovered polyomaviruses KI and WU (KIV and WUV) were isolated from secretions of patients with respiratory symptoms as well as in blood, spleen, lymphoid tissues, and stools, especially in immunocompromised conditions. The aim of this work was to evaluate the prevalence of KIV and WUV in bronchoalveolar lavage (BAL) from lung transplant recipients. We also examined potential correlations between these viruses and occurrences of pneumonia, acute respiratory insufficiency, or other acute respiratory conditions and acute rejection episodes. Discharge diagnosis was based on the International Classification of Diseases-Italian version 2002, based on the 9th-revision clinical modification. A rejection episode was diagnosed by transbronchial lung biopsy in accordance with the 2007 International Society for Heart and Lung Transplantation Working Formulation. Overall, we analyzed 53 BALs obtained from 24 transplant recipients. Positive polymerase chain reaction results were observed in 6 samples (11.3%) from 6 patients (25%), versus 7 samples (13.2%) from 7 patients (29.2%) for KIV and WUV, respectively. Regarding the diagnosis of pneumonia, the prevalence was 22.2% and 33.3% for KIV and WUV, respectively. In cases of acute respiratory insufficiency or other acute respiratory conditions, 2 out of 9 samples were positive for KIV (22.2%) and 4 out of 9 for WUV (44.4%). An Acute rejection episode (ARE) was diagnosed in 7 instances among 6 lung transplant patients: The corresponding BAL specimens showed positive results for KIV in 3 out of 7 (42.8%) cases with ARE vs 3 out of 46 (6.5%) without an ARE (P < .05), and for WUV in 3 out of 7 (42.8%) vs 4 out of 46 (8.7%) (P < .05), respectively. Although the small number of specimens limits the statistical analysis, our results showed a higher prevalence of WUV compared with KIV. The compromised pulmonary environment in the lung allograft may cause reactivation of these viruses. Their roles in this context need to be further evaluated.

Authors+Show Affiliations

Virology Unit, University Hospital S. Giovanni Battista, Turin, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20534279

Citation

Astegiano, S, et al. "Prevalence and Clinical Impact of Polyomaviruses KI and WU in Lung Transplant Recipients." Transplantation Proceedings, vol. 42, no. 4, 2010, pp. 1275-8.
Astegiano S, Bergallo M, Solidoro P, et al. Prevalence and clinical impact of polyomaviruses KI and WU in lung transplant recipients. Transplant Proc. 2010;42(4):1275-8.
Astegiano, S., Bergallo, M., Solidoro, P., Terlizzi, M. E., Libertucci, D., Baldi, S., Cavallo, R., & Costa, C. (2010). Prevalence and clinical impact of polyomaviruses KI and WU in lung transplant recipients. Transplantation Proceedings, 42(4), 1275-8. https://doi.org/10.1016/j.transproceed.2010.03.107
Astegiano S, et al. Prevalence and Clinical Impact of Polyomaviruses KI and WU in Lung Transplant Recipients. Transplant Proc. 2010;42(4):1275-8. PubMed PMID: 20534279.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence and clinical impact of polyomaviruses KI and WU in lung transplant recipients. AU - Astegiano,S, AU - Bergallo,M, AU - Solidoro,P, AU - Terlizzi,M E, AU - Libertucci,D, AU - Baldi,S, AU - Cavallo,R, AU - Costa,C, PY - 2010/6/11/entrez PY - 2010/6/11/pubmed PY - 2010/10/30/medline SP - 1275 EP - 8 JF - Transplantation proceedings JO - Transplant. Proc. VL - 42 IS - 4 N2 - The newly discovered polyomaviruses KI and WU (KIV and WUV) were isolated from secretions of patients with respiratory symptoms as well as in blood, spleen, lymphoid tissues, and stools, especially in immunocompromised conditions. The aim of this work was to evaluate the prevalence of KIV and WUV in bronchoalveolar lavage (BAL) from lung transplant recipients. We also examined potential correlations between these viruses and occurrences of pneumonia, acute respiratory insufficiency, or other acute respiratory conditions and acute rejection episodes. Discharge diagnosis was based on the International Classification of Diseases-Italian version 2002, based on the 9th-revision clinical modification. A rejection episode was diagnosed by transbronchial lung biopsy in accordance with the 2007 International Society for Heart and Lung Transplantation Working Formulation. Overall, we analyzed 53 BALs obtained from 24 transplant recipients. Positive polymerase chain reaction results were observed in 6 samples (11.3%) from 6 patients (25%), versus 7 samples (13.2%) from 7 patients (29.2%) for KIV and WUV, respectively. Regarding the diagnosis of pneumonia, the prevalence was 22.2% and 33.3% for KIV and WUV, respectively. In cases of acute respiratory insufficiency or other acute respiratory conditions, 2 out of 9 samples were positive for KIV (22.2%) and 4 out of 9 for WUV (44.4%). An Acute rejection episode (ARE) was diagnosed in 7 instances among 6 lung transplant patients: The corresponding BAL specimens showed positive results for KIV in 3 out of 7 (42.8%) cases with ARE vs 3 out of 46 (6.5%) without an ARE (P < .05), and for WUV in 3 out of 7 (42.8%) vs 4 out of 46 (8.7%) (P < .05), respectively. Although the small number of specimens limits the statistical analysis, our results showed a higher prevalence of WUV compared with KIV. The compromised pulmonary environment in the lung allograft may cause reactivation of these viruses. Their roles in this context need to be further evaluated. SN - 1873-2623 UR - https://www.unboundmedicine.com/medline/citation/20534279/Prevalence_and_clinical_impact_of_polyomaviruses_KI_and_WU_in_lung_transplant_recipients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(10)00443-4 DB - PRIME DP - Unbound Medicine ER -